[go: up one dir, main page]

EA201700464A1 - Производные майтанзиноида, их конъюгаты и способы использования - Google Patents

Производные майтанзиноида, их конъюгаты и способы использования

Info

Publication number
EA201700464A1
EA201700464A1 EA201700464A EA201700464A EA201700464A1 EA 201700464 A1 EA201700464 A1 EA 201700464A1 EA 201700464 A EA201700464 A EA 201700464A EA 201700464 A EA201700464 A EA 201700464A EA 201700464 A1 EA201700464 A1 EA 201700464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
methods
derivatives
maytanzinoid
help
Prior art date
Application number
EA201700464A
Other languages
English (en)
Other versions
EA034950B1 (ru
Inventor
Томас Ниттоли
Томас Маркотан
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201700464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of EA201700464A1 publication Critical patent/EA201700464A1/ru
Publication of EA034950B1 publication Critical patent/EA034950B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Заявляются майтанзиноидные производные, их конъюгаты и способы лечения или профилактики пролиферативных заболеваний с их помощью.
EA201700464A 2015-03-27 2016-03-25 Производные майтанзиноида, их конъюгаты и способы использования EA034950B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139044P 2015-03-27 2015-03-27
US201562252239P 2015-11-06 2015-11-06
PCT/US2016/024343 WO2016160615A1 (en) 2015-03-27 2016-03-25 Maytansinoid derivatives, conjugates thereof, and methods of use

Publications (2)

Publication Number Publication Date
EA201700464A1 true EA201700464A1 (ru) 2018-11-30
EA034950B1 EA034950B1 (ru) 2020-04-09

Family

ID=55650789

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700464A EA034950B1 (ru) 2015-03-27 2016-03-25 Производные майтанзиноида, их конъюгаты и способы использования

Country Status (17)

Country Link
US (3) US20160375147A1 (ru)
EP (1) EP3273998B1 (ru)
JP (2) JP6948950B2 (ru)
KR (2) KR20240142591A (ru)
CN (2) CN115645543A (ru)
AU (1) AU2016243527B2 (ru)
BR (1) BR112017020149A8 (ru)
CA (1) CA2978340C (ru)
CL (1) CL2017002422A1 (ru)
CO (1) CO2017010890A2 (ru)
EA (1) EA034950B1 (ru)
IL (1) IL254267B (ru)
MX (2) MX2017012380A (ru)
PH (1) PH12017501780A1 (ru)
SG (1) SG11201707148PA (ru)
WO (1) WO2016160615A1 (ru)
ZA (1) ZA201706040B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2996807T3 (en) 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
CN115645543A (zh) * 2015-03-27 2023-01-31 里珍纳龙药品有限公司 美登素类衍生物、其偶联物和使用方法
US11129903B2 (en) 2015-07-06 2021-09-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
ES2952735T3 (es) 2016-09-23 2023-11-03 Regeneron Pharma Anticuerpos anti-MUC16-CD3 biespecíficos y conjugados anti-MUC16-fármaco
BR112019005641A2 (pt) 2016-09-23 2019-07-30 Regeneron Pharma Anticorpos antisteap2, conjugados anticorpo-fármaco e moléculas de ligaçãoa antígeno biespecíficas que ligam steap2 e cd3, e usos dos mesmos
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
IL266917B2 (en) 2016-11-29 2023-10-01 Regeneron Pharma Anti-human prolactin receptor (prlr) antibody-drug conjugates and use thereof in combination therapy of prlr positive breast cancer
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
KR20200085807A (ko) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 항체 약물 접합제용 친수성 링커
EP3717018A1 (en) * 2017-11-30 2020-10-07 Centurion BioPharma Corporation Maytansinoid-based drug delivery systems
CA3097711A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
SG11202011232VA (en) 2018-05-17 2020-12-30 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
CN112638426B (zh) * 2018-09-21 2023-06-16 中国人民解放军军事科学院军事医学研究院 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
WO2020172475A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021097220A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
JP2023515941A (ja) 2020-02-28 2023-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法
MX2022012821A (es) 2020-04-16 2022-11-07 Regeneron Pharma Metodos de conjugacion de diels-alder.
MX2023004434A (es) 2020-10-22 2023-05-08 Regeneron Pharma Anticuerpos anti-fgfr2 y metodos para usarlos.
JP2023548975A (ja) 2020-11-10 2023-11-21 レジェネロン ファーマシューティカルズ， インコーポレイテッド セレン抗体複合体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
DK2135881T3 (da) 2005-06-20 2011-12-05 Genentech Inc Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
EP1912677B1 (en) 2005-06-20 2013-10-02 Psma Development Company, L.L.C. PSMA antibody-drug conjugates
EP1913002B9 (en) 2005-08-09 2012-04-25 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
CN103901208B (zh) 2005-12-22 2016-08-24 巴克斯特国际公司 能够更好地在医疗制品中检测非内毒素致热污染物的改进的单核细胞活化测试
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
CA2687178C (en) 2007-05-23 2014-02-04 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
US8969626B2 (en) 2008-07-21 2015-03-03 Polytherics Limited Reagents and method for conjugating biological molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP2013501766A (ja) 2009-08-10 2013-01-17 ユーシーエル ビジネス パブリック リミテッド カンパニー 固体基材の官能化
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
ES2612459T3 (es) 2010-08-02 2017-05-17 Regeneron Pharmaceuticals, Inc. Ratones que producen proteínas de unión que comprenden dominios VL
ES2611359T3 (es) 2011-05-27 2017-05-08 Ambrx, Inc. Composiciones que contienen, métodos que implican y usos de derivados de dolastatina ligados con aminoácidos no naturales
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
SG195172A1 (en) * 2011-06-21 2013-12-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
EA029046B1 (ru) 2011-10-14 2018-02-28 Медимьюн Лимитед Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
WO2013055990A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
FI3912642T3 (fi) 2012-10-23 2023-07-07 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
CN105849086B (zh) * 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
ES2996807T3 (en) 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
BR112016004023A2 (pt) * 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
CN115645543A (zh) * 2015-03-27 2023-01-31 里珍纳龙药品有限公司 美登素类衍生物、其偶联物和使用方法

Also Published As

Publication number Publication date
JP6948950B2 (ja) 2021-10-13
CA2978340A1 (en) 2016-10-06
AU2016243527A1 (en) 2017-09-21
ZA201706040B (en) 2020-05-27
CN115645543A (zh) 2023-01-31
IL254267A (en) 2018-06-28
IL254267B (en) 2021-03-25
KR20170131587A (ko) 2017-11-29
PH12017501780A1 (en) 2018-04-30
KR102708103B1 (ko) 2024-09-20
CL2017002422A1 (es) 2018-03-16
US20220259225A1 (en) 2022-08-18
CA2978340C (en) 2024-05-28
US20160375147A1 (en) 2016-12-29
SG11201707148PA (en) 2017-10-30
US20200385402A1 (en) 2020-12-10
BR112017020149A8 (pt) 2023-05-02
EA034950B1 (ru) 2020-04-09
JP2021113191A (ja) 2021-08-05
CO2017010890A2 (es) 2020-04-13
CN107995912A (zh) 2018-05-04
EP3273998B1 (en) 2019-09-04
EP3273998A1 (en) 2018-01-31
JP2018516851A (ja) 2018-06-28
KR20240142591A (ko) 2024-09-30
WO2016160615A1 (en) 2016-10-06
MX2017012380A (es) 2018-04-11
NZ735426A (en) 2024-09-27
MX2021008101A (es) 2021-08-05
BR112017020149A2 (pt) 2018-09-11
AU2016243527B2 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EA201700464A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EA039072B9 (ru) Производные майтанзиноида, их конъюгаты и способы применения
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
IL261920A (en) Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
ZA201703467B (en) Methods of treating ocular conditions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201591709A1 (ru) 5-бром-индирубины
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
EA201691907A1 (ru) Комбинированная терапия кураксинами